http://bmj.com/cgi/content/full/325/7355/90
| Home | Help | Search/Archive | Feedback | Table of Contents |
|
||||||||||
 Collections under
which this article appears: Pregnancy
Other
Infectious Diseases Molecular
Medicine Reproductive
medicine |
Lesson of the week
infection
or immunity?
Nilesh M Mehta
Neonatal Intensive Care Unit, Northwick Park Hospital, Harrow HA1 3UJ
Correspondence to: R M Thomas ros.thomas@nwlh.nhs.uk
Rubella vaccination among schoolgirls and susceptible women in the United Kingdom since 1970 has dramatically reduced the number of cases of congenital rubella syndrome and terminations of pregnancies related to rubella infection.1 In 1988 the combined measles, mumps, and rubella vaccine was introduced for children aged 12-15 months. Reported cases of congenital rubella syndrome declined significantly, with only a few notified cases of infection among immigrants and in infants whose mothers acquired the infection while travelling overseas in early pregnancy. Immune status of pregnant women is determined by routine antenatal screening for rubella IgG antibody, so that susceptible women can receive postpartum vaccination.
We report two infants with congenital rubella syndrome whose mothers had
recently arrived from abroad. Both mothers had a rash in early
pregnancy in their country of origin, which was not elicited when
they booked for antenatal care in the United Kingdom.
 |
Case reports |
|---|
 Top  Case reports
 Discussion
References
|
|---|
Case 1
A 22 year old primiparous Sri Lankan woman had routine antenatal
screening tests at 20 weeks' gestation, soon after her arrival in the
United Kingdom. The laboratory reported presence of rubella IgG
antibody, "consistent with immunity." The infant was born with severe
symmetrical intrauterine growth restriction, purpura,
thrombocytopenia, and a patent ductus arteriosus. Cranial
ultrasonography showed bilateral periventricular calcification (fig
1). Skeletal radiographs showed linear radiolucencies in
the metaphyses of the long bones and lucent areas in the iliac
bones, consistent with osteitis (fig 2). Ophthalmological
examination showed a unilateral cataract on the first day after birth
and progressive bilateral cataracts by 3 weeks of age. Congenital
rubella syndrome was suspected, and the mother confirmed that
she had had a transient rash at 6-8 weeks' gestation in Sri Lanka.
Rubella specific IgM was detected in the infant's blood taken at
11 days of age, and excretion of rubella virus was subsequently
confirmed in the infant's saliva and urine. Audiological testing
showed major bilateral sensorineural hearing loss by 12 weeks.
Retesting of the mother's antenatal serum with IgM and IgG avidity
tests gave results compatible with acquired rubella infection during
early gestation.
|
|
Case 2
Soon after her arrival in the United Kingdom a 29 year old
primiparous Nigerian woman gave birth at 38 weeks' gestation to an
infant with severe symmetrical intrauterine growth restriction. The
woman's antenatal tests in Nigeria did not include rubella screening.
The infant had interstitial pneumonitis, thrombocytopenia, and a
patent ductus arteriosus. Ophthalmological examination showed
bilateral cataracts by 3 weeks of age. Radiography showed linear
streaking of the metaphyses of the long bones. Diagnosis of congenital
rubella infection was confirmed by detection of rubella specific
IgM in blood at 3 weeks of age. Audiological testing showed moderate
sensorineural hearing loss by 8 months of age. The mother confirmed
a history of a rash in early gestation, around the time of diagnosis
of her pregnancy. Postnatal tests showed the presence of rubella
IgG antibody but absence of rubella specific IgM in the mother.
These findings are compatible with infection in early pregnancy, as
rubella specific IgM in the mother disappears 4-6 weeks after
infection.
| |
Discussion |
|---|
|
Top Case reports
Discussion
References
|
|---|
The major reduction in rubella infection since the introduction of measles, mumps, and rubella vaccination is well documented.2-4 However, missed opportunities for vaccination, decreased uptake of the vaccine, reinfection of mothers, and immigration from places where rubella is endemic have contributed to sporadic cases of congenital rubella syndrome in the United Kingdom.
Detection of rubella specific IgG, usually by enzyme linked immunosorbent
assay (ELISA), forms the basis of antenatal surveillance for rubella
immunitybut the test
does not discriminate between vaccine induced immunity and infection
acquired during early gestation. In most pregnant women the detection
of rubella specific IgG implies immunity following vaccination or
infection before pregnancy. However, this result should be
interpreted with caution, particularly in recent immigrants from
countries where rubella is endemic or where rubella vaccination is
not available or not effectively implemented. Racial differences in
rubella immunity among pregnant women have been reported. People's
exposure to natural infection and to vaccination will vary according
to the country where they were brought up. Susceptibility in Asian
women has been reported to be four times higher than in non-Asian
women.5
Detection of rubella IgG on antenatal screening tests in women who have recently arrived from countries where rubella is endemic may indicate rubella infection acquired in early gestation. Both women in our report had a clear history of a rash in early pregnancy, but this history had not been sought during their antenatal care in the United Kingdom, and the laboratory reported the result of the screening test as "rubella IgG antibody present, consistent with immunity." Clinicians should actively seek a history of rash in early gestation, particularly in recent immigrants, and the laboratory should be informed of a suspicious history so that the appropriate tests for primary rubella infection can be undertaken. The Public Health Laboratory Services Working Group has outlined advice to be given after these laboratory tests.6 A diagnostic difficulty arises in women tested more than 4-6 weeks after contracting rubella infection in early gestation, as IgM disappears and only IgG antibody is detected in serum. In such cases it is recommended to check past serum samples, if available, for IgG avidity to confirm recent seroconversion. Rarely, IgM positivity may be preceded by IgG positivity when serum is tested within 10 days of infection.
Congenital rubella infection can affect almost all organ systems in the fetus and has a high morbidity and mortality. Typical features of congenital rubella syndrome are cataracts, intrauterine growth restriction, thrombocytopenia, purpura, patent ductus arteriosus, osteitis, and hearing impairment. Microcephaly and chorioretinitis are also common. Periventricular calcification (case 1) has been reported previously in only a minority of infants with congenital rubella syndrome.7 It is more commonly associated with congenital cytomegalovirus and toxoplasma infection.
With the decline in uptake of the measles, mumps, and rubella vaccination, as
well as continuing reports of sporadic cases of congenital rubella
syndrome, especially among recent immigrants, clinicians need to be
aware of the range of clinical manifestations of this infection in
pregnant mothers and newborn infants. Early diagnosis of congenital
rubella syndrome is important, because infected infants may excrete
the virus in urine, saliva, and tears for many months and will be a
potential source of infection for non-immune pregnant women. Long
term follow up is essential, as cataracts and hearing deficit may not
be detectable until some months after birth and progressive
deterioration may occur.
| |
Acknowledgments |
|---|
Contributors: RMT was responsible for the care of the patients. NMM carried out the literature searches. Both authors wrote the paper. RMT will be the guarantor.
| |
Footnotes |
|---|
Funding: None.
Competing interests: None declared.
| |
References |
|---|
|
Top Case reports
Discussion
References
|
|---|
| 1. | Tookey PA, Peckham CS. Surveillance of congenital rubella in Great Britain, 1971-96. BMJ 1999; 318: 769-770[Full Text]. |
| 2. | Miller E, Waight P, Gay N, Ramsay M, Vurdien J, Morgan-Capner P, et al. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella immunisation campaign: fourth joint report from the PHLS and the National Rubella Surveillance Programme. Commun Dis Rep CDR Rev 1997; 7: R26-R32[Medline]. |
| 3. | Sullivan EM, Burgess MA, Forrest JM. The epidemiology of rubella and congenital rubella in Australia, 1992 to 1997. Commun Dis Intell 1999; 23: 209-214[Medline]. |
| 4. | Matter L, Bally F, Germann D, Schopfer K. The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme. Eur J Epidemiol 1995; 11: 305-310[Medline]. |
| 5. | Tookey PA, Johnson C, Ades AE, Peckham CS. Racial differences in rubella immunity among pregnant women. Public Health 1998; 102: 57-62. |
| 6. | Morgan-Capner P, Crowcroft N. Guidance on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). In: Report of a Public Health Laboratory Services Working Group. London: Public Health Laboratory Service, 2000. www.phls.co.uk/advice/rash.pdf (accessed 21 May 2002). |
| 7. | Rowen M, Singer MI, Moran ET. Intracranial calcification in the congenital rubella syndrome. Am J Roentgenol 1972; 115: 86. |
(Accepted 11 December 2001)
|
||||||||||
|
Collections under
which this article appears:Pregnancy
Other
Infectious Diseases Molecular
Medicine Reproductive
medicine |
Read all Rapid Responses
| Home | Help | Search/Archive | Feedback | Table of Contents |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.
